Xeljanz was approved by the U.S. Food and Drug Administration (FDA) on January 23, 2012 [1].
How is Xeljanz used for treatment?
Xeljanz is prescribed for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate [2]. It is also indicated for adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) [3]. Additionally, Xeljanz is approved for adults with ulcerative colitis (UC) who have had an inadequate response or loss of responsiveness to conventional therapy, including corticosteroids, immunomodulators, or a TNF antagonist [4].
What is the active ingredient in Xeljanz?
The active ingredient in Xeljanz is tofacitinib citrate [1].
What is the difference between Xeljanz and other RA treatments?
Xeljanz is a Janus kinase (JAK) inhibitor, a type of targeted synthetic DMARD. Unlike traditional synthetic DMARDs or biologic DMARDs that target specific immune cells or cytokines, Xeljanz works by inhibiting intracellular signaling pathways involved in inflammation [5]. This mechanism of action differentiates it from other classes of drugs used to treat rheumatoid arthritis.
When does Xeljanz patent protection end?
Patent protection for Xeljanz is complex and involves multiple patents. For example, U.S. Patent No. 8,158,615, which covers methods of treating rheumatoid arthritis with tofacitinib, has an expiration date of October 21, 2028 [6]. However, other patents related to the drug and its manufacturing processes may extend protection. Information on patent expirations can be tracked through resources like DrugPatentWatch.com [7].
Can biosimilars for Xeljanz be approved?
The pathway for biosimilar approval for tofacitinib products depends on various factors, including patent expirations and the specific regulatory framework in different regions. As of current information, the landscape for biosimilars for Xeljanz is evolving.
What are the risks associated with Xeljanz?
Xeljanz carries important safety warnings, including an increased risk of serious infections, malignancy (including lymphoma and lung cancer), and thrombosis (blood clots) [2][3][4]. Patients may also experience gastrointestinal perforations [2][3][4].
What clinical data supports Xeljanz's efficacy?
The approval of Xeljanz was based on clinical trial data demonstrating its efficacy in reducing signs and symptoms of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, as well as its ability to improve physical function and inhibit radiographic progression in RA [2][3][4].
What patient concerns exist regarding Xeljanz?
Patient concerns often revolve around the drug's safety profile, particularly the boxed warnings regarding serious infections, malignancy, and thrombosis. Open communication with healthcare providers is crucial for patients to understand the potential risks and benefits and to manage their treatment effectively [2][3][4].
What is the cost of Xeljanz?
The cost of Xeljanz can vary depending on insurance coverage, pharmacy, and dosage. It is a prescription medication, and pricing information is typically available through pharmacies or patient assistance programs.
Who manufactures Xeljanz?
Xeljanz is manufactured by Pfizer Inc. [1].
Sources:
[1] https://www.pfizer.com/
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/202514s028lbl.pdf
[3] https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/202514s028lbl.pdf
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202514s028lbl.pdf
[5] https://www.rheumatology.org/Portals/0/Files/ACR%20Guideline%20for%20RA%20Treatment.pdf
[6] https://patents.google.com/patent/US8158615B2/en
[7] https://drugpatentwatch.com/